Opposite effects of angiotensins receptors type 2 and type 4 on streptozotocin induced diabetes vascular alterations in mice

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Nasser, Mohamad ^a   Clere, Nicolas ^b   Botelle, Laurent ^a   Javellaud, James ^a   Oudart, Nicole ^a   Faure, Sébastien ^b   Achard, Jean Michel ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Angiotensin IV; AT2 receptor; AT4 receptor; Endothelial dysfunction; Streptozotocin induced diabetes

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME; VASODILATION;

EID: 84893690747     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-40     Document Type: Article

References (47)

1. Kannel W, McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2(2):120-126. 10.2337/diacare.2.2.120, 520114.
2. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation 2011, 124(16):1737-1746. 10.1161/CIRCULATIONAHA.111.022327, 3215589, 21947298.
3. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007, 3(6):853-876. 2350146, 18200806.
4. Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol 2012, 10(1):19-32. 10.2174/157016112798829797, 22112354.
5. Dzau V. Vascular wall renin-angiotensin pathway in control of the circulation. A hypothesis. Am J Med 1984, 77(4A):31-36.
6. Heagerty A, Aalkjaer C, Bund S, Korsgaard N, Mulvany M. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993, 21(4):391-397. 10.1161/01.HYP.21.4.391, 8458640.
7. Ross R. The pathogenesis of atherosclerosis. N Engl J Med 1986, 314(8):488-500. 10.1056/NEJM198602203140806, 3511384.
8. Patel BM, Mehta AA. Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur J Pharmacol 2012, 697(1-3):1-12.
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003. 10.1016/S0140-6736(02)08089-3, 11937178.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000, 342(3):145-153.
11. Hein L, Barsh G, Pratt R, Dzau V, Kobilka B. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995, 377(6551):744-747. 10.1038/377744a0, 7477266.
12. Siragy H, Inagami T, Ichiki T, Carey R. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999, 96(11):6506-6510. 10.1073/pnas.96.11.6506, 26912, 10339618.
13. Barber M, Sampey D, Widdop R. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999, 34(5):1112-1116. 10.1161/01.HYP.34.5.1112, 10567191.
14. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998, 16(12 Pt 2):2039-2043.
15. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. Hypertension 1998, 31(1 Pt 2):349-355.
16. Coleman JK, Krebs LT, Hamilton TA, Ong B, Lawrence KA, Sardinia MF, Harding JW, Wright JW. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 1998, 19(2):269-277. 10.1016/S0196-9781(97)00291-X, 9493859.
17. Kramar E, Krishnan R, Harding J, Wright J. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 1998, 74(2-3):185-192.
18. Vinh A, Widdop R, Drummond G, Gaspari T. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008, 77(1):178-187.
19. Vinh A, Widdop R, Chai S, Gaspari T. Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. Atherosclerosis 2008, 200(1):37-44.
20. Dowell F, Henrion D, Duriez M, Michel J. Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats. Br J Pharmacol 1996, 117(2):341-346. 10.1111/j.1476-5381.1996.tb15196.x, 1909273, 8789388.
21. Retailleau K, Belin de Chantemele EJ, Chanoine S, Guihot AL, Vessieres E, Toutain B, Faure S, Bagi Z, Loufrani L, Henrion D. Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries. Hypertension 2010, 55(2):339-344. 10.1161/HYPERTENSIONAHA.109.140236, 20026767.
22. Clere N, Faure S, Helesbeux J, Duval O, Andriantsitohaina R. Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells. Carcinogenesis 2011, 32(3):286-295. 10.1093/carcin/bgq260, 21135154.
23. Natarajan R, Gonzales N, Xu L, Nadler J. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 1992, 187(1):552-560. 10.1016/S0006-291X(05)81529-3, 1520346.
24. Alipui C, Ramos K, Tenner T. Alterations of rabbit aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovasc Res 1993, 27(7):1229-1232. 10.1093/cvr/27.7.1229, 8252581.
25. Creager M, Luscher T, Cosentino F, Beckman J. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Circulation 2003, 108(12):1527-1532. 10.1161/01.CIR.0000091257.27563.32, 14504252.
26. Lerman A, Zeiher A. Endothelial function: cardiac events. Circulation 2005, 111(3):363-368. 10.1161/01.CIR.0000153339.27064.14, 15668353.
27. Widlansky M, Gokce N, Keaney J. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42(7):1149-1160. 10.1016/S0735-1097(03)00994-X, 14522472.
28. Cooper M, Rumble J, Komers R, Du H, Jandeleit K, Chou S. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994, 43(10):1221-1228. 10.2337/diab.43.10.1221, 7926292.
29. Cooper M. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352(9123):213-219. 10.1016/S0140-6736(98)01346-4, 9683226.
30. Faure S, Chapot R, Tallet D, Javellaud J, Achard J, Oudart N. Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J Physiol Pharmacol 2006, 57(3):329-342.
31. Tiyerili V, Mueller CF, Becher UM, Czech T, van Eickels M, Daiber A, Nickenig G, Wassmann S. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice. J Mol Cell Cardiol 2012, 52(3):630-637. 10.1016/j.yjmcc.2011.12.007, 22230040.
32. Koitka A, Cao Z, Koh P, Watson AM, Sourris KC, Loufrani L, Soro-Paavonen A, Walther T, Woollard KJ, Jandeleit-Dahm KA, et al. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 2010, 53(3):584-592. 10.1007/s00125-009-1619-x, 19957160.
33. Avila M, Morgan J, Yan X. Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure. J Biomed Biotechnol 2011, 141039.
34. Widdop R, Jones E, Hannan R, Gaspari T. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br J Pharmacol 2003, 140(5):809-824. 10.1038/sj.bjp.0705448, 1574085, 14530223.
35. You D, Loufrani L, Baron C, Levy BI, Widdop RE, Henrion D. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 2005, 111(8):1006-1011. 10.1161/01.CIR.0000156503.62815.48, 2234478, 15710752.
36. Touyz RM, Endemann D, He G, Li JS, Schiffrin EL. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension 1999, 33(1 Pt 2):366-372.
37. Sabuhi R, Ali Q, Asghar M, Al-Zamily N, Hussain T. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 2011, 300(3):F700-F706. 10.1152/ajprenal.00616.2010, 3064141, 21209001.
38. Siragy H. The potential role of the angiotensin subtype 2 receptor in cardiovascular protection. Curr Hypertens Rep 2009, 11(4):260-262. 10.1007/s11906-009-0044-3, 19602326.
39. Steckelings UM, Paulis L, Unger T, Bader M. Emerging drugs which target the renin-angiotensin-aldosterone system. Expert Opin Emerg Drugs 2011, 16(4):619-630. 10.1517/14728214.2011.618495, 21905943.
40. Foulquier S, Steckelings UM, Unger T. Perspective: a tale of two receptors. Nature 2013, 493(7434):S9. 10.1038/493S9a, 23364772.
41. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlof B, Unger T. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2011, 11(2):187-192. 10.1016/j.coph.2010.11.002, 21167778.
42. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001, 276(52):48623-48626. 10.1074/jbc.C100512200, 11707427.
43. Vanderheyden PM. From angiotensin IV binding site to AT4 receptor. Mol Cell Endocrinol 2009, 302(2):159-166. 10.1016/j.mce.2008.11.015, 19071192.
44. Albiston AL, Fernando R, Ye S, Peck GR, Chai SY. Alzheimer's, angiotensin IV and an aminopeptidase. Biol Pharm Bull 2004, 27(6):765-767. 10.1248/bpb.27.765, 15187413.
45. Albiston AL, Diwakarla S, Fernando RN, Mountford SJ, Yeatman HR, Morgan B, Pham V, Holien JK, Parker MW, Thompson PE, et al. Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. Br J Pharmacol 2011, 164(1):37-47. 10.1111/j.1476-5381.2011.01402.x, 3171858, 21470200.
46. Faure S, Bureau A, Oudart N, Javellaud J, Fournier A, Achard JM. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens 2008, 26(10):2008-2015. 10.1097/HJH.0b013e32830dd5ee, 18806625.
47. Pham V, Albiston AL, Downes CE, Wong CH, Diwakarla S, Ng L, Lee S, Crack PJ, Chai SY. Insulin-regulated aminopeptidase deficiency provides protection against ischemic stroke in mice. J Neurotrauma 2012, 29(6):1243-1248. 10.1089/neu.2011.1824, 21895534.